17:12 , Aug 3, 2018 |  BC Week In Review  |  Clinical News

Sanofi drops two clinical assets; reports rebounding Dupixent sales

Sanofi (Euronext:SAN; NYSE:SNY) disclosed in its 2Q18 earnings that it ended development of antibody-drug conjugate (ADC) SAR566658 to treat triple-negative breast cancer (TNBC), as well as a recombinant subunit vaccine to treat tuberculosis. A Sanofi...
22:28 , Jul 31, 2018 |  BC Extra  |  Company News

Sanofi drops two clinical assets; reports rebounding Dupixent sales

Sanofi (Euronext:SAN; NYSE:SNY) disclosed in its 2Q18 earnings that it ended development of antibody-drug conjugate (ADC) SAR566658 to treat triple-negative breast cancer (TNBC), as well as a recombinant subunit vaccine to treat tuberculosis. A Sanofi...
19:19 , Jun 2, 2017 |  BC Week In Review  |  Company News

Sanofi, Immunogen amend financials of ADC deals

In exchange for $30 million, ImmunoGen Inc. (NASDAQ:IMGN) and Sanofi (Euronext:SAN; NYSE:SNY) eliminated potential milestone and royalties payments the biotech was eligible to receive under two deals involving five compounds. The candidates are isatuximab, SAR408701...
07:00 , Aug 11, 2014 |  BC Week In Review  |  Company News

Immco, Nicox deal

Immco Diagnostics Inc., a part of Trinity Biotech plc (NASDAQ:TRIB, Dublin, Ireland), granted Nicox exclusive rights in North America to commercialize the Sjo diagnostic panel to detect Sjogren’s syndrome, a systemic autoimmune disease that mainly...
08:00 , Nov 25, 2013 |  BC Week In Review  |  Company News

Nicox, Trinity, Sjogren's Syndrome Foundation sales and marketing update

Nicox launched the Sjo diagnostic panel from Immco Diagnostics Inc. , now part of Trinity, in the U.S. to detect Sjogren's syndrome. The test, which FDA approved earlier this year, has a list price of...
07:00 , Oct 28, 2013 |  BC Week In Review  |  Clinical News

HuDS6-DM4: Interim Phase I data

Interim data from 20 evaluable patients with refractory CAVI-positive solid tumors who received IV SAR566658 every 3 weeks at doses of >=120 mg/m 2 in an open-label, dose-escalation, international Phase I trial showed that the...
07:00 , Jun 24, 2013 |  BC Week In Review  |  Company News

Immco, Nicox sales and marketing update

Immco granted Nicox exclusive rights to promote Immco's Sjogren's syndrome lab-based diagnostic to eye care practitioners in North America and a nine-month option to negotiate an agreement to promote the test in the rest of...